Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment

Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment

Decitabine (DAC) is clinically used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Our genome-wide CRISPR-dCas9 activation screen using MDS-derived AML cells indicates that mitotic regulation is critical for DAC resistance. DAC strongly induces abnormal mitosis (abscission...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Tomohiro Yabushita, Takumi Chinen, Atsuya Nishiyama, Shuhei Asada, Ruka Shimura, Tomoya Isobe, Keita Yamamoto, Naru Sato, Yutaka Enomoto, Yosuke Tanaka, Tomofusa Fukuyama, Hitoshi Satoh, Keiko Kato, Kaori Saitoh, Takamasa Ishikawa, Tomoyoshi Soga, Yasuhito Nannya, Tatsuo Fukagawa, Makoto Nakanishi, Daiju Kitagawa, Toshio Kitamura, Susumu Goyama
Médium: Artigo
Jazyk:angličtina
Vydáno: 2023
On-line přístup:https://doi.org/10.1016/j.celrep.2023.113098
https://www.cell.com/article/S2211124723011099/pdf
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1016/j.celrep.2023.113098
https://www.cell.com/article/S2211124723011099/pdf

Podobné jednotky